Clinical Trials Directory

Trials / Completed

CompletedNCT00767871

Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder

Changes of Cerebral Glucose Metabolism Associated With the Fear Network Activity Before and After 12 Weeks of Escitalpram Treatment in Panic Disorder

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
46 (actual)
Sponsor
Samsung Medical Center · Academic / Other
Sex
All
Age
20 Years – 60 Years
Healthy volunteers
Accepted

Summary

Panic disorder is one of the most prevalent psychiatric disorders and recently abnormal fear network is known to be implicated in the pathophysiology of panic disorder. The fear network involves many brain regions such as amygdala, hippocampus, periaqueductal gray (PAG), locus coeruleus, parahippocampal gyrus, frontal cortex, and thalamus. Escitalopram, a highly selective serotonin reuptake inhibitor, is usually effective for panic dis order, but there is little information on how escitalopram affects the fear network. The specific aim of this study is to test the following hypotheses using 18F-FDG positron emission tomography (PET) 1. Patients with panic disorder will show abnormal activity of the fear network compared to healthy comparison subjects. 2. Patients with panic disorder will show normalized activity of the fear network after 12-weeks of treatment with escitalopram. 3. The changes of fear work after the treatment will be associated with psychological variables and neurohormones.

Conditions

Interventions

TypeNameDescription
DRUGLexapro12 week treatment with lexapro

Timeline

Start date
2007-03-01
Primary completion
2007-08-01
Completion
2008-12-01
First posted
2008-10-07
Last updated
2011-07-25

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT00767871. Inclusion in this directory is not an endorsement.